{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:08:37Z","timestamp":1788390517163,"version":"build-2803163510"},"reference-count":15,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2021,6]]},"abstract":"Was ist neu?<\/jats:title>\n Epidemiologie und Risikofaktoren\u2002Bei Personen mit HIV ist das Risiko f\u00fcr ein Non-Hodgkin-Lymphom (HIV-NHL) bzw. Hodgkin-Lymphom (HIV-HL) auch unter kombinierter antiretroviraler Therapie um das 10\u201320- bzw. 5\u201315-Fache erh\u00f6ht. Wichtige Risikofaktoren sind der CD4-Zell-Nadir und die kumulative HIV-Viruslast.<\/jats:p>\n Prognose\u2002Die Prognose wird durch den pathologischen Subtyp und den Internationalen Prognose-Index sowie durch die Zahl der CD4-Zellen bei Lymphom-Diagnose und durch molekulare Marker wie die Expression von MYC oder BCL2 bestimmt.<\/jats:p>\n Therapie\u2002Standardtherapie des diffus gro\u00dfzelligen B-Zell-Lymphoms sind 6 Zyklen R-CHOP. Patienten mit Burkitt-Lymphom erhalten eine Therapie nach dem B-ALL\/NHL-Protokoll der GMALL. F\u00fcr das plasmoblastische Lymphom ist keine Standardtherapie etabliert, Therapie der Wahl sind CHOP oder EPOCH plus Bortezomib. Die Prognose von Patienten mit prim\u00e4rem Erguss-Lymphom ist weiterhin ung\u00fcnstig. In kleinen Fallserien wurden relativ gute Ergebnisse mit DA-EPOCH \u00b1 Bortezomib erzielt. Die Ganzhirnbestrahlung ist bei Patienten mit HIV und prim\u00e4rem ZNS-Lymphom obsolet. Protokolle mit HD-MTX sind gut machbar und effektiv. Hodgkin-Lymphom: Stadien-adaptierte Therapie mit ABVD und\/oder BEACOPP basis. Bei Patienten mit rezidivierter oder refrakt\u00e4rer Erkrankung kommt eine Hochdosischemotherapie mit autologer Stammzelltransplantation zum Einsatz. Zudem gibt es zahlreiche Fallberichte zur erfolgreichen Therapie mit Nivolumab oder Pembrolizumab.<\/jats:p>\n Rezidivtherapie\u2002Die Rezidivrate nach kompletter Remission betr\u00e4gt bei Patienten mit NHL ca. 11\u200a%. Standardtherapie ist die autologe Stammzelltransplantation, sofern Patienten daf\u00fcr geeignet sind. Eine Therapie mit CAR-T-Zellen sollte HIV-Patienten nicht vorenthalten werden.<\/jats:p>","DOI":"10.1055\/a-1169-0848","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T22:34:30Z","timestamp":1622586870000},"page":"724-727","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostik und Therapie der HIV-assoziierten Lymphome: Update 2021"],"prefix":"10.1055","volume":"146","author":[{"given":"Marcus","family":"Hentrich","sequence":"additional","affiliation":[{"name":"Rotkreuzklinikum M\u00fcnchen, Abteilung f\u00fcr Innere Medizin III \u2013 H\u00e4matologie\/Onkologie, M\u00fcnchen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2352-3018(18)30360-6","article-title":"Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study","volume":"6","author":"R U Hern\u00e1ndez-Ram\u00edrez","year":"2019","journal-title":"Lancet HIV"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/bjh.13221","article-title":"Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort","volume":"168","author":"P Schommers","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.2019003959","article-title":"Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)","volume":"136","author":"J C Ramos","year":"2020","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"N L Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejca.2020.07.033","article-title":"Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era","volume":"138","author":"L Vasseur","year":"2020","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma","volume":"38","author":"M Roschewski","year":"2020","journal-title":"J Clin Oncol"},{"issue":"S 01","key":"ref7","first-page":"S239","article-title":"Characteristics and outcomes of HIV-related Burkitt-lymphoma (HIV-BL) in the post-rituximab era across 30 US cancer centers","volume":"4","author":"J Alderuccio","year":"2020","journal-title":"Hemasphere"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17515","article-title":"Characteristics and outcome of Human Immunodeficiency Virus (HIV)-associated Primary Effusion Lymphoma (PEL) as observed in the German\u00a0HIV-related lymphoma cohort study","author":"M Hentrich","year":"2021","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2019-01-893339","article-title":"Viral, immunologic, and clinical features of primary effusion lymphoma","volume":"133","author":"K Lurain","year":"2019","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/neuonc\/now155","article-title":"Long-term survival in AIDS-related primary central nervous system lymphoma","volume":"19","author":"N K Gupta","year":"2017","journal-title":"Neuro Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.2020006048","article-title":"Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate","volume":"136","author":"K Lurain","year":"2020","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2012.41.8137","article-title":"Stage-adapted treatment of human immunodeficiency virus associated Hodgkin lymphoma: results of a prospective multicenter study","volume":"30","author":"M Hentrich","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2017.180893","article-title":"Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study","volume":"103","author":"P Schommers","year":"2018","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41409-019-0480-x","article-title":"Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party","volume":"54","author":"K H\u00fcbel","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01018-7","article-title":"Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations","author":"J Allred","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1169-0848.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T23:05:32Z","timestamp":1623711932000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1169-0848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6,1]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1169-0848","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}